FindTrial
Sign In

Autologous CAR-T cells

BIOLOGICAL3 trials

Sponsors

Hebei Senlang Biotechnology Inc., Ltd., Shanghai Pudong Hospital, The Affiliated People's Hospital of Ningbo University

Conditions

Acute Myeloid Leukemia (AML)B-cell Acute Lymphoblastic Leukemia (B-ALL)B-cell Non-Hodgkin's Lymphoma (B-NHL)LeukemiaLymphomaMultiple Myeloma (MM)Multiple Myeloma of Bone (Diagnosis)Myeloma

Phase 1

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
NCT03312205
Hebei Senlang Biotechnology Inc., Ltd.Leukemia, Lymphoma, Multiple Myeloma of Bone (Diagnosis)
Start: 2017-08-29End: 2023-08-29Target: 50Updated: 2019-01-09
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
WithdrawnNCT05513612
Shanghai Pudong HospitalAcute Myeloid Leukemia (AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), B-cell Non-Hodgkin's Lymphoma (B-NHL) +2
Start: 2020-08-01End: 2026-12-31Updated: 2023-03-01
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
RecruitingNCT05528887
The Affiliated People's Hospital of Ningbo UniversityLeukemia, Lymphoma, Myeloma +1
Start: 2021-09-16End: 2026-06-30Target: 10Updated: 2022-09-06

Related Papers

Factors Associated with Outcomes Among Refractory/Relapsed TP53-Mutated/Chromosome 17p Deletion Acute B-Cell Lymphoblastic Leukemia (B-ALL) Patients Treated with CD19-Targeted Chimeric Antigen Receptor (CAR)-T Therapy
Blood2021-11-053 citations
Preliminary results of phase I/II study of SENL-B19 chimeric antigen receptor T cell therapy in pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r-ALL)
Annals of Oncology2018-10-011 citations